Compare
ImageneBio, Inc. vs Pluri Inc. vs Cardiff Oncology, Inc. vs Inhibrx Biosciences, Inc.
| Latest fiscal year | ImageneBio, Inc. IMA | Pluri Inc. PLUR | Cardiff Oncology, Inc. CRDF | Inhibrx Biosciences, Inc. INBX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $800.0K | $1.02M | $593.0K | $1.30M |
| Revenue growth (YoY) | -77.1% | -24.0% | -13.2% | +550.0% |
| Gross margin | n/a | 44.6% | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$45.35M | -$23.82M | -$45.85M | -$140.06M |
| EPS (Diluted) | -$9.64 | -$2.44 | -$0.69 | -$9.04 |
| Operating cash flow | -$47.84M | -$19.59M | -$37.92M | -$129.79M |
| Free cash flow | n/a | -$20.22M | -$37.97M | -$129.82M |
| Cash & equivalents | $94.53M | $3.53M | $17.47M | $124.22M |
| Total assets | $152.98M | $24.88M | $61.88M | $146.48M |
| Total liabilities | $19.84M | n/a | $16.50M | $138.49M |
| Shareholders' equity | $133.14M | -$23.04M | $45.39M | $7.99M |
| Return on year-end equity | -34.1% | n/a | -101.0% | n/m |
| Shares outstanding | n/a | 10.82M | 68.31M | 14.58M |
Revenue, most recent five fiscal years
| Fiscal year | ImageneBio, Inc. | Pluri Inc. | Cardiff Oncology, Inc. | Inhibrx Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $800.0K Ended 2025-12-31 | $1.02M Ended 2026-06-30 | $593.0K Ended 2025-12-31 | $1.30M Ended 2025-12-31 |
| 1 year earlier | $3.50M Ended 2024-12-31 | $1.34M Ended 2025-06-30 | $683.0K Ended 2024-12-31 | $200.0K Ended 2024-12-31 |
| 2 years earlier | $9.16M Ended 2023-12-31 | $326.0K Ended 2024-06-30 | $488.0K Ended 2023-12-31 | $1.80M Ended 2023-12-31 |
| 3 years earlier | $15.62M Ended 2022-12-31 | $287.0K Ended 2023-06-30 | $386.0K Ended 2022-12-31 | n/a |
| 4 years earlier | $30.98M Ended 2021-12-31 | $234.0K Ended 2022-06-30 | $359.0K Ended 2021-12-31 | n/a |